Risk of Trisomy 21 After Age 35
The age-related risk of trisomy 21 at delivery for a 35-year-old woman is approximately 1 in 356, and this risk increases progressively with advancing maternal age, reaching approximately 1 in 34 (34 per 1000 births) for women 45 years and older 1, 2.
Age-Specific Risk Stratification
The risk of Down syndrome increases in an almost exponential pattern between ages 15 and 45, though the curve flattens at older maternal ages 3. Here's what you need to know:
Baseline Age-Related Risks
- At age 35: The risk at delivery is approximately 1 in 356 1
- Ages 35-40: Risk increases progressively with each year
- Ages 40-41: False-positive screening rates approach 50% due to high baseline risk 4
- Age 45 and older: Risk plateaus at approximately 1 in 34 (34 per 1000 births), which is considerably lower than previously assumed 2
The lower-than-expected risk at very advanced maternal ages (≥45 years) is likely explained by higher spontaneous miscarriage rates of trisomy 21 pregnancies in this age group 2.
Gestational Age Considerations
Risk varies significantly by gestational age due to spontaneous fetal loss:
- At 12 weeks gestation: Risk is approximately 30% higher than at term 5
- At 16 weeks gestation: Risk is approximately 21% higher than at term 5
- First trimester (11-14 weeks): Use a risk cutoff of approximately 1 in 200 (equivalent to a 35-year-old's first-trimester risk) 6
- Second trimester: Use a risk cutoff of approximately 1 in 270 (equivalent to a 35-year-old's second-trimester risk) 7, 6
The formula for adjusting term risk to trimester-specific risk: multiply term risk by 1.75 for first trimester and 1.3 for second trimester 6.
Screening Performance in Women ≥35 Years
Traditional Serum Screening
The quadruple screen (AFP, hCG, uE3, inhibin-A) combined with maternal age detects over 80% of Down syndrome fetuses in women 35 and older, with a 5% positive screening rate 7.
Combined First Trimester Screening
Nuchal translucency plus PAPP-A and free β-hCG detects approximately 77-82% of trisomy 21 cases when using appropriate risk cutoffs 8, 4. However, the false-positive rate increases dramatically with maternal age:
- 6.6% at age 35
- ~50% at ages 40-41
- Nearly 100% in women over 41 4
Cell-Free DNA (cfDNA) Screening
cfDNA is the most accurate screening test available and dramatically reduces residual risk 1, 9. A negative cfDNA result lowers the risk of trisomy 21 by 300-fold, reducing a 35-year-old woman's risk to less than 1 in 50,000 1.
Clinical Decision-Making Algorithm
For women ≥35 years:
Offer comprehensive counseling about age-related risks and all screening/diagnostic options 9
First-line screening approach: cfDNA screening is recommended as it provides superior detection rates (>99% for trisomy 21) with the lowest false-positive rates 10
If cfDNA is negative: No further aneuploidy testing is recommended solely based on maternal age, as residual risk is negligible 1
If cfDNA is positive: Diagnostic confirmation with amniocentesis or CVS is mandatory before any pregnancy management decisions 9
If patient declines screening: Offer diagnostic testing (amniocentesis or CVS) directly, as this was historically the standard approach for women ≥35 years 7, 9
Important Caveats
Common pitfalls to avoid:
Do not perform diagnostic testing based solely on isolated soft ultrasound markers after negative cfDNA or serum screening, as the residual risk remains negligibly low 1
Do not use age 35 as an absolute threshold for offering testing—all pregnant patients should be informed about screening options regardless of age 10
Remember that cfDNA does not screen for neural tube defects—second-trimester maternal serum AFP and/or detailed anatomy ultrasound remain necessary 9
Be aware that most Down syndrome births occur in women under 35 simply due to higher birth rates in younger women, despite lower individual risk 11
Additional Risk Factors
Beyond maternal age, Hispanic ethnicity, male fetal sex, and multiparity are associated with modestly increased risk in both younger and older women 11. In older women specifically, young paternal age (20-24 years) and Hispanic paternal ethnicity also increase risk 11.